 \
            
             &
            
        
    
            Contact us
            
            \
            
             &
            
        
    
            Contact us
        
This was 7 months ago
LocationOnline
ProgrammesThis webinar, organised by the EU IP Helpdesk, will address the key IP issues which need to be addressed in business collaborations, particularly for SMEs and startups, in order to best use these intellectual assets as strategic tools to maintain competitiveness, enable growth and business expansion, and support investment.
At the end of the webinar, you will have a better understanding of:
More information and registration here.
                We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020). 
                Stay informed about what matters to you.
                By signing up, you can opt in for e-mail notifications and get access to
                a personalised dashboard that groups all news updates and event announcements in your domain(s).
            
Only for stakeholders located in Flanders
 
                        
                    The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.